Thale Dawn Hovdun Patrick-Brown

Thale Dawn Hovdun Patrick-Brown
Oslo University Hospital · Division of Surgery, Inflammatory Diseases and Transplantation

BSc, MSc MIET

About

4
Publications
598
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
30
Citations
Citations since 2016
4 Research Items
30 Citations
201620172018201920202021202202468101214
201620172018201920202021202202468101214
201620172018201920202021202202468101214
201620172018201920202021202202468101214
Introduction
Thale is a professional research project manager working with the SolidAct COVID-19 trial (Trøseid Group, Oslo University Hospital, Clinic for Surgery, Inflammation Medicine and Transplantation - KIT), the EuroPMP COST Action project (Flatmark Group, Institute for Cancer Research, Oslo University Hospital) and the Molecular Mechanisms of Ageing group (Evandro F. Fang, Akershus University Hospital/University of Oslo).
Additional affiliations
September 2020 - present
Norway Health Tech
Position
  • Consultant
August 2020 - present
Orthrus Project Management AS
Position
  • CEO
May 2020 - present
Oslo University Hospital
Position
  • Project Manager
Education
September 2012 - April 2018
Heriot-Watt University
Field of study
  • Engineering (Geoeconomic Modeling, Taxation, Neural Networks)
September 2005 - April 2008
University of Reading
Field of study
September 1998 - March 2002
University of Lethbridge
Field of study
  • Neuroscience

Publications

Publications (4)
Chapter
While extracellular Aβ plaques and intracellular tau tangles are the classical disease-defining pathological features of Alzheimer’s disease (AD), defective mitophagy, and consequently, the accumulation of damaged mitochondria increase risk of AD and exacerbate AD progression. Mitophagy is a cellular autophagic process that selectively recognizes a...
Article
Full-text available
Background The determination of the incidence and prevalence of rare diseases is important for economists and health-care providers. Pseudomyxoma peritonei (PMP) is a rare, slow-growing abdominal cancer that represents a substantial burden on both patients and health-care systems. The incidence rate was previously approximated at 1–2 people per mil...
Article
Full-text available
Background and purpose: We investigated how features relating to pelvic cavity anatomy and tumor hemodynamic factors may influence systemic failure in rectal cancer. Materials and methods: Rectal cancer patients (207 women, 343 men), who had been prospectively enrolled onto six cohorts and given curative-intent therapy, were analyzed for the fir...

Network

Cited By

Projects

Projects (3)
Project
Diagnosis and follow-up of PMP patients is based on radiological imaging (CT or MRI) and blood tests for detection of protein tumor markers (CEA, CA 19-9 and CA 125). Classic cases are easily recognized by expert radiologists in the field, but since PMP is a rare disease, it is often misdiagnosed or the diagnostic process is protracted. After CRS-HIPEC, radiological findings at follow-up are initially subtle, often leaving uncertainty regarding diagnosis of recurrence with resulting anxiety on the part of the patient. The blood biomarkers available are not specific to PMP, and in many cases these blood tests are normal even when tumor is present. Thus, available methods lack both sensitivity and specificity, and diagnosis and follow-up of PMP is challenging. New diagnostic methods should be highly sensitive, preferably minimally invasive, and based on properties specific to PMP. The current project is based on in-depth knowledge of the molecular composition of PMP (specific mutations), generated from analysis of a large number of patient samples. The hypothesis is that these mutated DNA fragments from the tumor can be detected in plasma samples from PMP patients. The project will utilize state-of-the-art technologies to analyze samples from our extensive biobank of PMP samples.
Project
Pseudomyxoma peritonei (PMP) is a rare abdominal cancer originating in the appendix, causing extensive tumour growth in the peritoneal cavity. Although rare, PMP still dramatically affects the lives of almost 4,000 new persons in Europe every year, posing a huge financial and logistical challenge for health-care providers. If complete surgical removal cannot be accomplished at expert centres, prognosis is very poor, and no other effective treatments are currently available. Because it is a rare disease, research into the pathogenesis, classification, molecular composition and treatment of PMP has been fragmented and challenging. The EuroPMP Action aims to sculpt a new, collaborative landscape within PMP research through the creation of a strong and capable network of experts from many fields, including surgeons, pathologists, oncologists, radiologists, molecular biologists, bioinformaticians and allied health care professionals. The Action will work towards a cure for PMP through the facilitation of collaborative research projects, the sharing and dissemination of knowledge, and the improvement of standards of care for the thousands of patients afflicted with PMP.
Project
The potential for the use of PD-1 checkpoint inhibition to increase the efficacy of standard Nordic FLOX therapy for colorectal cancer.